Summary: Researchers unmasked a critical cellular transition that dictates whether Alzheimer’s disease pathology triggers clinical dementia. The research analyzed brain tissue from older adults, including cognitively healthy centenarians, to map how the brain’s resident immune cells, microglia, alter their behavioral states in response to pathological proteins.

The findings establish that cognitive resilience is an active cellular mechanism driven by distinct microglial programs that can uncouple amyloid-beta and tau accumulation from neurodegeneration, offering high-priority therapeutic pathways to arrest disease progression before a definitive cognitive tipping point is crossed.

Key Facts

• The Pathology Paradox: Alzheimer’s disease affects over 55 million people globally, but the presence of classic amyloid-beta plaques and tau tangles does not automatically guarantee a dementia diagnosis. Some individuals maintain flawless cognitive health despite heavy biomarker burdens, pointing to an active cellular resilience mechanism.
• Mapping Six Distinct Tissue Domains: Utilizing high-resolution spatial transcriptomics and single-cell sequencing on human donor material, the team successfully identified six distinct tissue zones that characterize the spatial and temporal stages of Alzheimer’s progression.
• The Inflammatory to Antigen-Presenting Transition: Investigators unmasked a profound behavioral pivot in microglial state programming:
  • Early Stage: Microglia adopt a highly localized inflammatory state tightly bound to amyloid-beta plaques.
  • Late Stage: The cells transition into an antigen-presenting immune state that emerges alongside destructive tau pathology and active neurodegeneration.
• Two Distinct Routes to Resilience: The data revealed that the brain can actively resist clinical decline through two separate age-dependent biological pathways:
  • The Octogenarian Track: Individuals in their 80s who accumulated extensive plaque burdens without developing dementia showed the early microglial response but successfully blocked the transition into the late-stage degenerative immune state.
  • The Centenarian Track: Cognitively healthy individuals over the age of 100 activated the late-stage microglial program, but the response was entirely uncoupled from tau accumulation and harmful neurodegenerative effects.
• Targeting the Tipping Point: Lead authors Professor Bart De Strooper and Professor Mark Fiers emphasize that future therapeutic intervention must target these specific microglial shifts, particularly pathways like TREM2, to preserve early beneficial responses before inflammatory states cross the threshold into tau-driven cognitive decline.

Source: VIB

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer’s disease pathology leads to dementia.

Studying brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians, the team identified distinct cellular programs and immune-cell states associated with disease progression and resilience.

Their findings, published in Nature Medicine, suggest that changes in microglia—the brain’s resident immune cells—could represent an important target for future Alzheimer’s therapies. 

“This has been an exciting journey with many partners. The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia,” says Prof. Bart De Strooper (VIB-KU Leuven Center for Neuroscience, KU Leuven), ERC grantee and one of the co-senior authors of the study. 

Alzheimer’s disease affects more than 55 million people worldwide and is marked by the accumulation of amyloid-β plaques and tau tangles in the brain. Yet the relationship between these hallmarks and dementia is not straightforward: some individuals remain cognitively healthy despite having plaques and tangles. Scientists increasingly believe that the answer lies in how different brain cells respond to these proteins.

Among the most important players are microglia, the brain’s immune cells, whose activity changes dramatically as the disease progresses. Understanding these cellular responses could reveal why some people are resilient to Alzheimer’s disease and help identify new therapeutic targets. 

The new study reveals that individuals who remain cognitively healthy despite Alzheimer’s pathology do so through distinct biological mechanisms. By comparing the brains of people with and without dementia, as well as cognitively healthy centenarians (people over the age of 100 years), the researchers identified unique microglial responses associated with resilience against Alzheimer’s disease, providing new insights into how the brain can resist the effects of the condition. 

“Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia,” adds Prof. Mark Fiers (VIB-KU Leuven), co-senior author of the study. 

Mapping a critical transition in Alzheimer’s disease 

To investigate this resilience, the research team combined technologies that can analyze tissues at the level of single cells (spatial transcriptomics and single-cell sequencing), and they identified six distinct tissue domains representing different stages of Alzheimer’s disease progression. A key turning point emerged between domains associated primarily with amyloid-β plaques and those linked to tau pathology and neurodegeneration. 

This transition was accompanied by a striking change in microglia. Early in the disease process, these cells adopted an inflammatory state associated with amyloid plaques. Later, they switched to a distinct antigen-presenting state that appeared alongside the emergence of tau pathology. The findings suggest that this cellular transition may represent a critical step determining whether Alzheimer’s pathology progresses toward dementia. 

Two different routes to resilience 

The study also revealed that resilience to Alzheimer’s disease can arise through different biological mechanisms. Octogenarians who accumulated amyloid plaques but remained free of dementia showed an early microglial response but did not transition into the later immune state associated with disease progression. 

Centenarians displayed a different pattern. Although they activated the later microglial program, this response occurred largely independently of tau accumulation. In other words, a cellular state linked to neurodegeneration in some individuals appeared to be uncoupled from harmful effects in others. These findings suggest that resilience is not simply the absence of pathology, but the brain’s ability to alter how it responds to it. 

These insights could help guide the development of more precise therapies. Molecules aimed at preserving beneficial early microglial responses and involved in microglial state transitions could represent valuable therapeutic targets. Moreover, interventions may be most effective when applied before the brain reaches the tipping point where inflammatory responses become linked to tau pathology and cognitive decline. 

“These findings open new opportunities to target microglial states — especially pathways such as TREM2 — and extend resilience rather than simply focusing on plaque removal. We are excited to continue this journey and understand the causal role of microglial transitions leading to the identification of novel therapeutic approaches to delay or prevent disease progression,” concludes Niels Plath, CSO of Muna Therapeutics  

Key Questions Answered:

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this Alzheimer’s disease research news

Author: Gunnar De Winter
Source: VIB
Contact: Gunnar De Winter – VIB
Image: The image is credited to Neuroscience News

Original Research: Open access.
“Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience” by Ashley Lu, Wei-Ting Chen, Maria Dalby, Diego Sainz Garcia, Marisa Vanheusden, Luuk E. de Vries, Veerle van Lieshout, Araks Martirosyan, Katleen Craessaerts, Sebastiaan Moonen, Magdalena Zielonka, Iordana Chrysidou, Anke Misbaer, Leen Wolfs, Benjamin Pavie, Dick Swaab, Dietmar Rudolf Thal, Inge Huitinga, Annemieke Rozemuller, Susan Karijn Rohde, Marc Hulsman, Henne Holstege, Rita Balice-Gordon, Niels Plath, Mark Fiers & Bart De Strooper. Nature Medicine
DOI:10.1038/s41591-026-04393-8

Abstract

Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience

Alzheimer’s disease (AD) is not an inevitable outcome of pathology but a dynamic process shaped by how brain cells respond to amyloid-β (Aβ) and tau.

To disentangle these responses, we combined spatial transcriptomics and single-nucleus RNA sequencing of the superior frontal cortex from octogenarians living with or without dementia and from cognitively intact centenarians with comparable Aβ accumulation.

We identified six distinct tissue domains representing a spatial pathological continuum of AD, with a key inflection point marked by a shift from Aβ-associated inflammatory changes to tau-associated cellular programs.

This transition was accompanied by a change in microglial states, from early inflammatory to late antigen-presenting phenotypes, termed early and late plaque-induced gene (PIG) programs. Resilient individuals showed distinct pathological patterns: octogenarians without dementia lacked late PIGs, whereas centenarians showed late PIG activation that was uncoupled from tau accumulation.

Together, these findings highlight divergent resilience-associated mechanisms in human aging and position microglial state transitions at the Aβ−tau interface as candidate points of resilience with potential therapeutic relevance.